J&J's Q3 pharma sales increase by 5% as it awaits Remicade decision
This article was originally published in Scrip
Johnson & Johnson reported third-quarter sales of $15.0 billion, a drop of 1% of the same period last year. However, the company raised its earnings guidance for the full year to $4.70-$4.80 per share, reflecting recent currency exchange rates and excluding special items.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.